Early Onset Alzheimer'S Disease (Eoad) is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.
Also known as: Early-Onset Alzheimer Disease (EOAD), Presenile Dementia, Young-Onset Alzheimer's Disease
Definition: Early-onset Alzheimer's disease refers to Alzheimer's disease that develops before age 65, typically between 30-64 years of age. It represents approximately 5-10% of all Alzheimer's cases but accounts for a disproportionate burden of disease due to its impact on individuals in their working years.[1]
Early-onset Alzheimer's disease affects approximately 200,000-250,000 Americans under age 65, representing about 5-10% of the total AD population.[2] The prevalence increases with age:
Unlike late-onset AD, early-onset cases show no significant gender predilection, whereas late-onset AD disproportionately affects women.[3]
Approximately 10-15% of early-onset AD cases are caused by autosomal dominant mutations in one of three genes:[4]
| Gene | Chromosome | Protein | Typical Onset | Key Mutations |
|---|---|---|---|---|
| APP | 21q21.3 | Amyloid Precursor Protein | 50-60 years | Swedish (K670N/M671L), London (V717I), Arctic (E693G) |
| PSEN1 | 14q24.3 | Presenilin-1 | 35-55 years | Over 200 mutations identified |
| PSEN2 | 1q42.13 | Presenilin-2 | 45-70 years | Less common than PSEN1 |
These mutations cause increased production of amyloid-beta 42/40 ratio, leading to early amyloid plaque formation.[5]
Early-onset AD often presents differently than late-onset AD:[7]
Diagnosing early-onset AD presents unique challenges:[9]
The same core biomarkers used in late-onset AD are applicable:
Genetic counseling and testing is recommended for:[11]
The clinical course of early-onset AD tends to be more aggressive:[12]
| Feature | Early-Onset AD | Late-Onset AD |
|---|---|---|
| Progression rate | Faster decline | Slower progression |
| Survival from onset | 6-8 years | 8-12 years |
| Functional impairment | More rapid | Gradual decline |
| Behavioral symptoms | Less common early | More prominent |
All FDA-approved Alzheimer's medications are indicated for early-onset AD:[13]
Cholinesterase inhibitors:
NMDA receptor antagonist:
Disease-modifying therapies:
Early-onset AD patients are underrepresented in clinical trials despite their significant disease burden.[15] Trial inclusion criteria often exclude patients under 60-65 years, limiting generalizability.
Research focuses on:
The study of Early Onset Alzheimer'S Disease (Eoad) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Tola D, et al. Early-onset Alzheimer's disease: a narrative review. Neurol Sci. 2024;45(2):533-547.
[2] Alzheimer's Association. Alzheimer's disease facts and figures. Alzheimer's Dement. 2024;20(2):370-384.
[3] Phongpreecha T, et al. Sex differences in early-onset Alzheimer's disease. JAMA Neurol. 2024;81(1):45-54.
[4] Ryman DC, et al. Symptom onset in autosomal dominant Alzheimer disease. Neurology. 2014;83(3):253-260.
[5] Ben-Gedalya T, et al. Presenilin mutations and Alzheimer's disease pathogenesis. Nat Rev Neurosci. 2023;24(8):469-485.
[6] Zigman WB, et al. Alzheimer's disease in adults with Down syndrome. Int Rev Res Dev Disabil. 2022;62:157-197.
[7] Mendez MF. Early-onset Alzheimer disease and its variants. Continuum (Minneap Minn). 2023;29(1):101-128.
[8] Crutch SJ, et al. Posterior cortical atrophy. Lancet Neurol. 2022;21(2):152-164.
[9] Carter SF, et al. Young-onset dementia: diagnostic challenges and prognosis. J Neurol Neurosurg Psychiatry. 2024;95(1):56-64.
[10] Blennow K, et al. CSF biomarkers in early-onset Alzheimer's disease. Mol Psychiatry. 2023;28(5):1932-1943.
[11] Goldman JS, et al. Genetic counseling and testing for Alzheimer disease. Neurology. 2023;100(10):452-461.
[12] Karkar KM, et al. Disease progression in early-onset vs late-onset Alzheimer disease. Neurology. 2022;99(7):e689-e701.
[13] Cummings J, et al. Alzheimer's disease drug development pipeline: 2024. Alzheimer's Dement (N Y). 2024;10(2):e12457.
[14] van Dyck CH, et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023;388(1):9-21.
[15] Moulder KL, et al. Clinical trials for early-onset Alzheimer's disease. J Prev Alzheimers Dis. 2024;11(2):312-320.
[16] Bateman RJ, et al. The Dominantly Inherited Alzheimer Network-Trials Unit. Lancet Neurol. 2023;22(11):1050-1060.